XDXueting Deng

Xueting Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xueting Deng has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Lin Miao

    Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

    9 shared publications
  • Yang Yang

    Medical Center for Digestive Diseases, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China

    6 shared publications
  • Fei Wang

    Medical Center for Digestive Diseases, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China

    5 shared publications
  • Wei Zhou

    Department of Child Health Care, Children’s Hospital of Nanjing Medical University, Nanjing, China

    4 shared publications
  • Xianxiu Ge

    Medical Center for Digestive Diseases, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China

    4 shared publications
  • Xueyan Cao

    Medical Center for Digestive Diseases, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China

    4 shared publications

Latest Publications

  • Open Access

    Editorial Expression of Concern: Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation

    by Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng, Lin Miao

  • Open Access

    Gut Microbiota Mitigates Chronic Itch and Cutaneous Inflammation in DNFB-Induced Atopic Dermatitis Mice

    by Zichen Xiong, Xinming Dong, Yi Yuan, Lin Lu, Xueting Deng

    Chronic itch is the most prominent symptom of atopic dermatitis (AD), which severely impacts the quality of life of patients and persists even after medication. Gut microbiota dysbiosis is considered to contribute to AD, however, the roles of gut microbiota in the modulation of chronic pruriceptive processing currently remain unclear. The present study aimed to elucidate the potential regulatory role of the gut microbiota in AD-associated chronic itch. In this study, the 1-fluoro-2,4-dinitrobenzene (DNFB)-induced mouse model of AD-associated chronic itch was established. Differences in gut microbiota composition between model and healthy controls were analyzed using high-throughput 16S rRNA gene sequencing. In addition, we performed oral fecal microbiota transplantation (FMT) from model mice to antibiotic cocktail-treated healthy mice and observed whether they could induce itch behavior. Furthermore, feces from healthy mice were transplanted into model mice to evaluate their effects on itch symptoms and skin inflammation. The DNFB induced significantly itch behaviors and an altered gut microbiota composition. The gut microbiota from chronic itch mice through oral administration could induce itch behaviors in antibiotic cocktail-treated healthy mice. While, oral FMT from healthy mice to chronic itch mice not only significantly alleviated scratching behavior but also ameliorated skin damage and inflammation. Following FMT administration from healthy donors, remarkable alterations were observed in the metabolomic profiles of mice with DNFB-induced chronic itch. These findings highlight the potential link between gut microbiota dysbiosis and chronic itching in AD, suggesting that targeting the gut microbiota may be a therapeutic strategy for chronic itch.

  • Open Access

    A prognostic nomogram for predicting overall survival in gastric signet ring cell carcinoma patients: a SEER database and Chinese registry analysis

    by Jie Wu, Jichen Wang, Ning Chen, Junjie Nie, Ling Xia, Quanpeng Li, Xueting Deng, Guozhong Ji

    Purpose: Gastric signet ring cell carcinoma (GSRC) is a distinct gastric cancer (GC) subtype. This study aimed to develop and validate a nomogram to predict overall survival (OS) and guide clinical decision-making. Methods: This study included 2,203 GSRC patients from the SEER database (2010–2019), randomly split into a modeling cohort (n = 1,542) and an internal validation cohort (n = 661). An external cohort of 74 patients from the Second Affiliated Hospital of Nanjing Medical University (2019–2024; median follow-up 34 months) was used for validation. Predictor variables—age, sex, chemotherapy, lymph node ratio (LNR), T and M categories, tumor size, and tumor number—were included in a cox proportional hazard model. A nomogram was derived from the cox model and internally validated using 1,000 bootstrap resamples. Discrimination, calibration, and decision curve analysis (DCA) evaluated model performance. Results: The nomogram included age, chemotherapy, LNR, T and M categories, and tumor size. In the modeling cohort, time-dependent area under the receiver operating characteristic curve (AUC) was 0.79, 0.85, and 0.85 at 12, 36, and 60 months; internal validation AUCs were 0.79, 0.85, and 0.85. In the external cohort, AUC at 36 months was 0.91 (primary horizon), with exploratory IPCW-AUCs of 1.00 at 12 and 60 months due to class imbalance. Calibration showed close agreement between predicted and observed OS, and DCA demonstrated clinical net benefit across relevant thresholds. Conclusion: This study developed a nomogram for OS prediction in GSRC patients, supporting risk stratification and clinical decision-making.


  • Open Access

    APOA1 promotes tumor proliferation and migration and may be a potential pan-cancer biomarker and immunotherapy target

    by Peiyi Xu, Qiuyan Zhang, Jing Zhai, Pu Chen, Xueting Deng, Lin Miao, Xiuhua Zhang


  • Open Access

    Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types

    by Peiyi Xu, Qiuyan Zhang, Jing Zhai, Pu Chen, Xueting Deng, Lin Miao, Xiuhua Zhang

    Background ZBTB11 is a putative transcription factor with an N-terminal BTB domain and tandem C-terminal zinc finger motifs. Recent studies have suggested a potential role for ZBTB11 in tumorigenesis. However, the biological significance of ZBTB11 in different cancer types remains uncertain. Methods The expression levels, prognostic values, genetic mutations, and DNA promoter methylation of ZBTB11 across tumor types were explored via various online websites and databases, including TIMER2.0, GEPIA2, cBioPortal, UALCAN, GSCA, CancerSEA, and others. Additionally, a competing lncRNA-miRNA network of ZBTB11 was constructed, and its interaction with chemicals and genes was investigated. Results Our findings revealed that ZBTB11 was aberrantly expressed in a multitude of tumor types and exhibited variability across various tumor stages. A survival analysis revealed that ZBTB11 predicted a poor prognosis in BRCA, KIRP, LIHC, PCPG, PRAD, SARC, UCEC, and a good prognosis in CHOL, ESCA, GBM, KIRC, and READ. We also found that the most frequent genetic alterations type of ZBTB11 was mutation, and the DNA methylation level of ZBTB11 decreased in various cancers. Furthermore, ZBTB11 expression correlated with immune cells infiltration and genetic markers of immunodulators in cancers. Moreover, the results of single-cell sequencing demonstrated that ZBTB11 could regulate several tumor biological behaviors, including apoptosis, DNA damage, and angiogenesis. A lncRNA-miRNA network regulating ZBTB11 expression in tumor development and progression was constructed. It is of particular significance that ZBTB11 demonstrated a correlation with the CTRP and GDSC drug sensitivity, and that it served as a mediator between chemicals and cancers. Conclusion These findings demonstrate that ZBTB11 is associated with multiple tumor types and disease prognosis. ZBTB11 may represent a potential key biomarker and therapeutic target in cancers.


  • Open Access

    Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer

    by Luohang Ni, Jianing Xu, Quanpeng Li, Xianxiu Ge, Fei Wang, Xueting Deng, Lin Miao

    Biliary tract cancer (BTC) represents a challenging malignancy characterized by aggressive behavior, high relapse rates, and poor prognosis. In recent years, immunotherapy has revolutionized the treatment landscape for various cancers, but its efficacy in BTC remains limited. This article provides a comprehensive overview of the advances in preclinical and clinical studies of immunotherapy for BTC. We explore the potential of immune checkpoint inhibitors in reshaping the management of BTC. Despite disappointing results thus far, ongoing clinical trials are investigating the combination of immunotherapy with other treatment modalities. Furthermore, research on the tumor microenvironment has unveiled novel targets for immunotherapeutic interventions. By understanding the current state of immunotherapy in BTC and highlighting future directions, this article aims to fuel further exploration and ultimately improve patient outcomes in this challenging disease.


  • Neurokinin‐1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma

    by Yang Yang, Xueyan Cao, Yuting Wang, Xinyu Wu, Ping Zhou, Lin Miao, Xueting Deng

    Background: Intrahepatic cholangiocarcinoma (iCCA) has a poor prognosis and limited treatment options. Aprepitant, a selective NK‐1R antagonist, can inhibit the growth of various tumours in vitro and in vivo. However, it remains unclear whether aprepitant has cytotoxic effects on iCCA.Methods: We measured the expression of SP/NK‐1R in clinical samples of iCCA by immunohistochemistry. Then, we detected the cytotoxic effects of aprepitant on iCCA cells via MTT, EdU and colony formation assay. We constructed a subcutaneous xenograft model of BALB/c nude mice by using HCCC‐9810 and RBE cell lines to explore the effects of aprepitant in vivo. To elucidate the potential mechanisms, we explored the pro‐apoptotic effect of aprepitant by flow cytometric, western blotting, ROS detection and JC‐1 staining. Furthermore, we detected the autophagic level of HCCC‐9810 and RBE by western blotting, mRFP‐eGFP‐LC3 adenovirus transfection and electron microscope.Results: SP/NK‐1R is significantly expressed in iCCA. Aprepitant inhibited human iCCA xenograft growth and dose‐dependently decreased the viability of RBE and HCCC‐9810 cells. Aprepitant‐induced mitochondria‐dependent apoptosis through ROS/JNK pathway. Additionally, pretreatment with z‐VAD‐fmk partly reversed the effect of aprepitant on cell viability, while NAC completely attenuated the cytotoxic effects of aprepitant in vitro. Furthermore, we observed the dynamic changes of autophagosome in RBE and HCCC‐9810 cells treated with aprepitant.Conclusion: SP/NK‐1R signalling is significantly activated in iCCA and promotes the proliferation of iCCA cells. By contrast, aprepitant can induce autophagy and apoptosis in iCCA cells via ROS accumulation and subsequent activation of JNK.


  • Open Access

    Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation

    by Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng, Lin Miao

    Background: Aprepitant, as a neurokinin-1 receptor (NK-1R) antagonist, originally applied for curing chemotherapy-induced nausea and vomiting, has been reported to have significant antitumor effect on several malignant tumors. However, the effect of aprepitant on gallbladder cancer (GBC) is not clear yet. This study aimed to investigate the anti-tumor activity of aprepitant on GBC and the potential mechanisms. Methods: The NK-1R expression of gallbladder cancer cells were examined by immunofluorescence. MTT assay, wound healing and transwell migration assay were applied to detect the effect of aprepitant on cell proliferation, migration and invasion. Flow cytometry was used to detect the apoptosis rate. The effects of aprepitant on the expressions of cytokine were examined by real-time quantitative PCR and MAPK activation were detected via immunofluorescence and western blotting. Besides, xenograft model was established to investigate the effect of aprepitant in vivo. Results: Our results indicated that NK‐1R was markedly expressed in gallbladder cancer cells and aprepitant effectively inhibited the proliferation, migration and invasion. Furthermore, the apoptosis, ROS and inflammation response were significantly boosted by aprepitant in GBC. Aprepitant induced NF‐κB p65 nuclear translocationin and increased the expressions of p-P65, p-Akt, p-JNK, p-ERK and p-P38, as well as the mRNA levels of inflammatory cytokines IL-1β, IL-6 and TNF-α. Consistently, aprepitant suppressed the growth of GBC in xenograft mice model. Conclusion: Our study demonstrated that aprepitant could inhibit the development of gallbladder cancer via inducing ROS and MAPK activation, which suggested that aprepitant may become a promising therapeutic drug against GBC.


  • Open Access

    Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis through ROS/JNK pathway in intrahepatic cholangiocarcinoma

    by Yang Yang, Xueyan Cao, Yuting Wang, Xinyu Wu, Ping Zhou, Lin Miao, Xueting Deng

    Intrahepatic cholangiocarcinoma (iCCA) has a poor prognosis and limited treatment options. Aprepitant, a selective NK-1R antagonist, is capable of inhibiting the growth of various tumors in vitro and in vivo. To investigate the cytotoxic effects of aprepitant on the intrahepatic cholangiocarcinoma, we confirmed the expression of SP/NK-1R in clinical samples of iCCA by immunohistochemistry. MTT test showed that aprepitant could suppress cell viability of RBE and HCCC-9810. Meanwhile, aprepitant induced mitochondria-dependent apoptosis through ROS/JNK pathway in a dose-dependent manner. Additionally, anti-apoptotic drug z-VAD-fmk pretreatment could partly improve the decrease of cell viability induced by aprepitant, while ROS scavenger, NAC could cancel the cytotoxic effects of aprepitant in vitro. Therefore, these results indicated that autophagy is another downstream process of aprepitant-induced ROS accumulation. Changes in the expression of autophagy-related proteins and number of autophagosomes were detected by western blotting and electron microscopy, respectively. Furthermore, we observed the dynamic changes of autophagosome in RBE and HCCC-9810 treated with aprepitant by using mRFP-eGFP-LC3 adenovirus transfection. Moreover, aprepitant significantly inhibited the growth of iCCA xenografts. These findings reveal NK-1R as an potential therapeutic target against iCCA and highlight the anti-cancer ability of NK-1R antagonist aprepitant in iCCA.

  • Open Access

    Aprepitant Inhibits JNK and p38/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain

    by Yang Yang, Wei Zhou, Xiuqi Xu, Xianxiu Ge, Fei Wang, Guang-Qin Zhang, Lin Miao, Xueting Deng

    Substance P contributes to the pathogenesis of pain by acting on NK-1R, specialized sensory neurons that detect noxious stimuli. Aprepitant, an antagonist of NK-1R, is widely used to treat chemotherapy-induced nausea and vomiting. In this study, we used LPS-stimulated BV-2 microglia cell line and animal models of inflammatory pain to explore the analgesic effect of aprepitant on inflammatory pain and its underlying mechanism. The excitability of DRG neurons were measured using whole-cell patch-clamp recordings. The behavioral tests were measured and the morphological changes on inflamed paw sections were determined by HE staining. Changes in the expressions of cytokine were measured by using real-time quantitative PCR analysis and ELISA method. Immunofluorescence and western blotting were used to detect the microglia activation and MAPK. Aprepitant treatment significantly inhibited the excitability of DRG neurons. The pain behavior and the paw tissues inflammatory damage were significantly relived after the administration of aprepitant compared to formalin group. Aprepitant significantly suppressed the activation of microglia, phosphorylation of JNK and p38 MAPK, as well as the mRNA and protein expressions of MCP-1, TNF-α, IL-6, and IL-1β, in vivo and in vitro. The LPS-induced over-translocation into nucleus of NF-κBp65 was down-regulated following aprepitant treatment in BV-2 cells. The present study suggests that aprepitant attenuates inflammatory pain in mice via suppressing the phosphorylation of JNK and p38, and inhibiting the NF-κB signaling pathway.